Accelerating Research
The University of Adelaide is committed to supporting our world-class researchers achieve commercial outcomes through the translation of research, but we need your support.
Help us enhance our leadership position in research, technology innovation and commercialisation by supporting this critical point in technology development.
Your contribution will be used in conjunction with University funding, which is currently undertaken through our university-funded Commercial Accelerator Scheme (‘CAS’), to provide researchers with the resourcing they need to increase the commercial readiness of the technology by providing funds for proof of concept and the early stages of development.
This crucial funding, which is so hard to come by, helps our researchers develop their technology to a point where it’s ready to be licensed to an industry partner or spin-out ready to attract venture capital funding.
In 2022 the University of Adelaide generated:
• 66 invention disclosures.
• 33 technology licences.
• $7.6m in research commercialisation income.
As of 31 December 2022, we held:
• Equity in 10 start-ups based on University IP valued at $25m.
• 80 active patent families.
Your gift
Your gift today will help provide researchers of the University of Adelaide with the resources they need to develop their technology ready for market.
Case Studies
Bygen Pty Ltd
Dr Philip Kwong, Lewis Dunnigan, Benjamin Morton, and Jon Marshall (School of Chemical Engineering) developed technology that allows for the conversion of waste products into high-quality activated carbon.
The University invested $100k to support a $220k funding application to the SA Government. This facilitated the creation of spin-out company Bygen with access to $320k start-up funds.
Bygen has continued to develop and recently announced it has begun construction of a plant in Swan Reach that is sized to produce at least 1500-2000 tonnes of activated carbon per year.
Structural Health Monitoring System
Dr Noune Melkoumian (School of Mining and Petroleum Engineering) received funding to develop a network based structural health monitoring system that can monitor and detect potential structural faults in bridges, tunnels, and buildings.
This resulted in licensing to a Queensland robotic structural monitoring company for local and global manufacturing and launch to market in the building, transport, and mining sector.
Development of pathology-activated drugs for the treatment of neuropathic pain
Prof Andrew Abell and Dr Thomas Avery (School of Physics, Chemistry and Earth Sciences), and University of Texas Researchers Prof Peter Grace and Dr Jiahe Li developed pathology-activated drugs for the treatment of neuropathic pain. The University of Adelaide supported the project with $100k to cover technology development and patent expenses.
In 2023 the research team was awarded USD6.2M over five years in National Institutes of Health (NIH) funding through a collaborator from the University of Texas.